Last reviewed · How we verify
A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus radiotherapy and S-1 for treatment of refractory or metastatic esophageal squamous cell carcinoma.
Details
| Lead sponsor | Hebei Medical University Fourth Hospital |
|---|---|
| Phase | PHASE2 |
| Status | TERMINATED |
| Enrolment | 7 |
| Start date | Wed Nov 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Dec 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Refractory or Metastatic Esophageal Squamous Cell Carcinoma
Interventions
- apatinib S-1 radiotherapy
- S-1 radiotherapy
Countries
China